Natixis Advisors LLC Acquires 3,042 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Natixis Advisors LLC boosted its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 27.1% in the fourth quarter, Holdings Channel reports. The institutional investor owned 14,287 shares of the company’s stock after buying an additional 3,042 shares during the period. Natixis Advisors LLC’s holdings in Medpace were worth $4,747,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the business. Madison Investment Advisors LLC bought a new position in Medpace in the 4th quarter valued at approximately $2,308,000. Balboa Wealth Partners bought a new position in Medpace in the 4th quarter valued at approximately $201,000. HBK Sorce Advisory LLC raised its holdings in Medpace by 0.5% in the 4th quarter. HBK Sorce Advisory LLC now owns 5,384 shares of the company’s stock valued at $1,789,000 after buying an additional 29 shares during the last quarter. Skandinaviska Enskilda Banken AB publ raised its holdings in Medpace by 6.2% in the 4th quarter. Skandinaviska Enskilda Banken AB publ now owns 169,697 shares of the company’s stock valued at $56,546,000 after buying an additional 9,948 shares during the last quarter. Finally, Erste Asset Management GmbH increased its position in Medpace by 45.3% during the 4th quarter. Erste Asset Management GmbH now owns 17,546 shares of the company’s stock valued at $5,928,000 after purchasing an additional 5,469 shares during the period. Institutional investors own 77.98% of the company’s stock.

Medpace Stock Up 1.4 %

Shares of MEDP opened at $324.23 on Friday. Medpace Holdings, Inc. has a 12-month low of $302.01 and a 12-month high of $459.77. The business’s fifty day moving average is $337.72 and its 200 day moving average is $339.89. The stock has a market cap of $9.88 billion, a P/E ratio of 25.67, a P/E/G ratio of 3.81 and a beta of 1.47.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. On average, analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Analysts Set New Price Targets

Separately, Robert W. Baird increased their target price on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, Medpace has an average rating of “Hold” and an average target price of $381.44.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.